Race Oncology Ltd. (AU:RAC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd successfully held its Annual General Meeting with all resolutions carried on a poll. The company’s focus remains on advancing its lead asset, bisantrene, in the fight against cancer, offering a promising therapeutic with reduced cardiotoxicity and significant potential in oncology treatment. Investors may find Race’s strategic collaborations and pursuit of commercial opportunities noteworthy as they aim to expand bisantrene’s reach globally.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.